Antimicrobial Therapy as a Risk Factor of Multidrug-Resistant Acinetobacter Infection in COVID-19 Patients Admitted to the Intensive Care Unit

Table 4

Univariate analysis of the association between possible risk factors and the risk of MDR-Ab isolation.

Variable	Odds ratio (95% confidence interval)
Age (years)	1.01 (0.97–1.04)	0.664
Length of ICU stay exceeding 11 days	2.20 (1.27–3.81)	0.001
Diabetes mellitus	1.10 (0.79–1.53)	0.649
Obesity	0.79 (0.46–1.35)	0.497
Tocilizumab therapy	1.45 (1.08–1.94)	0.004
Mechanical ventilation	1.56 (0.97–2.50)	0.051
Previous ceftriaxone exposure	1.83 (1.16–2.87)	0.004
Previous meropenem exposure	1.03 (0.85–1.25)	0.559
C-reactive protein (mg/L)	1.00 (0.99–1.01)	0.604
Glomerular filtration rate (ml/s)	1.17 (0.42–3.30)	0.329
Neutrophil count (×1000 cells/ml)	1.06 (0.98–1.14)	0.683
Lymphocyte count (×1000 cells/ml)	1.07 (0.77–1.47)	0.573
CD4+ lymphocyte count (cells/ml)	1.00 (1.00–1.00)	0.732

ICU: intensive care unit; MDR-Ab: multidrug-resistant Acinetobacter; P: probability.